1. Novo Nordisk to acquire Emisphere Technologies

    and obtain ownership of the Eligen® SNAC oral delivery technology

  2. COVID-19 & diabetes

    If you have questions about physical and mental concerns during COVID-19, click the link below.

  3. Driving change

    We drive change to defeat diabetes and other serious chronic diseases.

  4. COVID-19 & obesity

    If you live with obesity, staying home for a prolonged period can make weight management difficult.

Latest news

{{'2020-11-17T14:24:44Z' | dateFormatFilter}}

Once-weekly semaglutide 2.0 mg demonstrates superior reduction in HbA1c vs once-weekly semaglutide 1.0 mg in people with type 2 diabetes in the SUSTAIN FORTE trial

Read more

{{'2020-11-15T22:30:42Z' | dateFormatFilter}}

Gilead and Novo Nordisk present new data from proof-of-concept trial in NASH

Read more

{{'2020-11-06T06:30:36Z' | dateFormatFilter}}

Novo Nordisk to acquire Emisphere Technologies and obtain ownership of the Eligen® SNAC oral delivery technology

Read more

News archive

Career Opportunities

Dear colleague

You are in the wrong place, click here to go directly to our internal career site to view all our current job opening.

Here are our current job openings. If there is not a job you are looking for, you are welcome to create a job agent or a candidate profile.

Dear colleague

You are in the wrong place, click here to go directly to our internal career site to view all our current job opening.

Investors

Share price

{{priceData.date}} {{priceData.time}}

{{priceData.currentPrice}} {{priceData.currency}}
Go to stock watch {{priceData.change}} {{priceData.currency}}

Quick links

View financial results Visit Capital Markets day News & IR Materials

Annual Report

Roshi has type 1 diabetes and lives in India.

Annual Report 2019

Download Annual Report

Novo Nordisk Headquarters in Denmark.